奥莱玛制药
OLMA
6.58
-0.29
-4.22%
奥莱玛制药
US · OLMA
#3521 按市值排名
上市于 2020
6.58
-0.29
-4.22%
实时 - 追踪5344个代码 - 心跳于74秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了2.8个百分点。
机构持股
- 机构持股比例
- 118.36% -2.79pp
- 机构数量
- 224 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund59.26%
Hedge Fund34.40%
VC/PE Fund17.68%
Public Company4.74%
Individual/Insider2.68%
Family Office/Trust1.15%
Private Company0.59%
Government Pension Fund0.36%
Insurance Company0.17%
主要股东 截至 2026-06-30
FMR
13.88% · 12.14M 股
Paradigm Biocapital Advisors LP
9.91% · 8.67M 股
Janus Henderson Group plc
8.11% · 7.09M 股
Bain Capital Life Sciences Investors, LLC
8.10% · 7.09M 股
BlackRock
7.67% · 6.71M 股
BVF Partners L.P.
6.05% · 5.30M 股
Artal Group S.A.
5.55% · 4.86M 股
State Street Global Advisors
4.93% · 4.32M 股
Vanguard Capital Management, LLC
4.29% · 3.76M 股
Logos Global Management, L.P.
3.67% · 3.21M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Cyrus Harmon | Director | 0.94% |
| David Myles | Chief Discovery & Non-Clinical Development Officer | 0.80% |
| Andrew Rappaport | Independent Director | 0.44% |
| Sean Bohen | Chief Executive Officer | 0.27% |
| Cynthia Butitta | Independent Director | 0.10% |
| Sasha Austin | VP of Finance & Controller | 0.02% |
| Naseem Zojwalla | Chief Medical Officer | 0.01% |
| Ian T. Clark | Independent Chairperson of the Board | -- |
| BVF Partners L.P. | -- | -- |
| Sandra Horning | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-31 | Jason O'Byrne | -- | Other Derivative Acquisition | +650,000 | $10.56 |
| 2026-07-23 | Cyrus Harmon | Director | Open Market Disposition | -25,000 | $11.58–11.71 |
| 2026-07-23 | Cyrus Harmon | Director | Intent to Sell (Form 144) | -12,500 | $11.71 |
| 2026-07-22 | Cyrus Harmon | Director | Intent to Sell (Form 144) | -12,500 | $11.58 |
| 2026-06-17 | Andrew Rappaport | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Ian T. Clark | Independent Chairperson of the Board | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | BVF Partners L.P. | -- | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Sandra Horning | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Scott Garland | Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Graham L. Walmsley | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Yi Larson | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Prakash Raman | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Gorjan Hrustanovic | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Cyrus Harmon | Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-04-27 | Prakash Raman | Independent Director | Other Derivative Acquisition | +27,061 | $14.59 |
| 2026-03-15 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -100,000 | $16.08 |
| 2026-03-15 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -4,166 | $16.61 |
| 2026-03-10 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -50,000 | $15.94 |
| 2026-03-09 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -53,206 | $17.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奥莱玛制药 讨论区 0 条评论